FDA Said No. HHS Said Maybe: The New Peptide Compounding Policy

On this episode of The Regulatory Mix, the discussion focuses on a major new policy shift affecting peptide compounding under Section 503A.

HHS has announced an interim enforcement discretion policy allowing certain state-licensed pharmacies, federal facilities, and licensed physicians to compound drug products using six specified peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, provided the policy’s conditions are met.

The significance is not that these peptides are now FDA-approved or formally added to the 503A Bulks List. Rather, HHS is creating an interim pathway while formal rulemaking continues. That makes this a meaningful change for compounders, prescribers, and patients who have been operating in a much more restrictive environment around these substances.

The policy also comes with significant conditions around sourcing, analytical testing, labeling, adverse event reporting, patient-specific prescriptions, route of administration, and product configuration. In other words, this is not a blanket green light. It is a tightly conditioned enforcement discretion framework.

The bigger story is what this signals about the future of peptide compounding. HHS is clearly willing to create a controlled pathway for certain high-interest peptides while formal regulatory processes catch up, but the quality and documentation expectations remain substantial.

The takeaway: this may open the door for peptide compounding, but it does not remove the need for strong sourcing controls, validated testing, patient-specific prescribing, and disciplined quality oversight.

Sources: HHS Federal Register Public Inspection Notice: https://public-inspection.federalregister.gov/2026-22192.pdf

HHS 503A Peptide Enforcement Discretion Policy — Appendix B: https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Disclosure: Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

Sponsored by Tailwind Pharma, LLC, a pharmaceutical quality and regulatory consulting firm specializing in FDA inspections, CGMP compliance, sterile manufacturing, data integrity, investigations, and regulatory strategy. Learn more at tailwindconsult.com.